<DOC>
	<DOCNO>NCT00971802</DOCNO>
	<brief_summary>To evaluate safety tolerability PF-03882845 Healthy Volunteers . To evaluate pharmacokinetics PF-03882845 Healthy Volunteers . To evaluate pharmacodynamics PF-03882845 Healthy Volunteers .</brief_summary>
	<brief_title>A Study To Evaluate The Safety , Tolerability , Pharmacokinetics , And Pharmacodynamics Of PF-03882845 In Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant disease . Past medical history epididymitis , orchitis , sexually transmit disease ( chlamydia , gonorrhea , etc . ) urinary tract infection . History prostatitis prostate surgery . Urinary catheterization instrumentation within 12 month screen . Inguinal scrotal hernia . Current history congenital genital abnormality . Baseline scrotal ultrasound scan show unilateral bilateral scrotal blood flow abnormality anatomic abnormality ( hydrocele , cyst , ) , exception small epididymal cyst spermatocele . Any condition possibly affect drug absorption ( eg , gastrectomy ) . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . History sensitivity spironolactone , eplerenone , related compound . Serum potassium &gt; 5.5 mEq/L screen Day 0 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>